NCT00001076View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 1997

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (3)

14642

Univ. of Rochester AVEG, Rochester

35294

UAB AVEG, Birmingham

63104

St. Louis Univ. School of Medicine AVEG, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH